Table 2. Results of one-way sensitivity analyses comparing apixaban to adjusted-dose warfarin: parameters for which variations result in positive incremental cost-effectiveness ratios.
Variable | Low range | High range | Threshold value* |
Apixaban drug cost, 2 weeks ($) | Dominant | 35,583 | 106 |
ICH bi-weekly costs, $ | 26,659 | Dominant | 2,418 |
ICH hazard ratio | Dominant | 12,049 | 0.49 |
Percentage of ICH that are fatal, % | Dominant | 1,111 | 44.0 |
Baseline rate of ICH on warfarin, % per year | 4,899 | Dominant | 0.70 |
Cost of warfarin treatment including cost of INR laboratory test, 2 weeks ($) | 2,156 | Dominant | 6.3 |
ICH = intracranial hemorrhage; INR = international normalized ratio.
Value of variable at which apixaban was no longer found to be a dominant economic strategy.